FBXO22

Across TCGA pan-cancer cohorts, FBXO22 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FBXO22 data layer compared with 20 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FBXO22 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FBXO22 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, HNSC, and UCEC are the cancer types where FBXO22 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.495	0.249	.001	33	view →
HNSC	DFS	Median	All	0.698	1.000	.020	13	view →
UCEC	DFS	Median	All	0.959	0.847	.019	6	view →
CCRCC	OS	Median	All	0.909	1.000	.019	5	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.386	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FBXO22–PDAC (DFS)

Open the PDAC breakdown →